Tags

Type your tag names separated by a space and hit enter

What pulmonologists think about the asthma-COPD overlap syndrome.

Abstract

BACKGROUND

Some patients with COPD may share characteristics of asthma; this is the so-called asthma-COPD overlap syndrome (ACOS). There are no universally accepted criteria for ACOS, and most treatments for asthma and COPD have not been adequately tested in this population.

MATERIALS AND METHODS

We performed a survey among pulmonology specialists in asthma and COPD aimed at collecting their opinions about ACOS and their attitudes in regard to some case scenarios of ACOS patients. The participants answered a structured questionnaire and attended a face-to-face meeting with the Metaplan methodology to discuss different aspects of ACOS.

RESULTS

A total of 26 pulmonologists with a mean age of 49.7 years participated in the survey (13 specialists in asthma and 13 in COPD). Among these, 84.6% recognized the existence of ACOS and stated that a mean of 12.6% of their patients might have this syndrome. In addition, 80.8% agreed that the diagnostic criteria for ACOS are not yet well defined. The most frequently mentioned characteristics of ACOS were a history of asthma (88.5%), significant smoking exposure (73.1%), and postbronchodilator forced expiratory volume in 1 second/forced vital capacity <0.7 (69.2%). The most accepted diagnostic criteria were eosinophilia in sputum (80.8%), a very positive bronchodilator test (69.2%), and a history of asthma before 40 years of age (65.4%). Up to 96.2% agreed that first-line treatment for ACOS was the combination of a long-acting β2-agonist and inhaled steroid, with a long-acting antimuscarinic agent (triple therapy) for severe ACOS.

CONCLUSION

Most Spanish specialists in asthma and COPD agree that ACOS exists, but the diagnostic criteria are not yet well defined. A previous history of asthma, smoking, and not fully reversible airflow limitation are considered the main characteristics of ACOS, with the most accepted first-line treatment being long-acting β2-agonist/inhaled corticosteroids.

Authors+Show Affiliations

Pneumology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain ; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.Respiratory Department, Hospital de Alta Resolucion de Loja, Granada, Spain.Medical-Surgical Unit of Respiratory Diseases, Virgen del Rocio University Hospital, Biomedicine Institute of Seville (IBiS), Seville, Spain.Department of Pneumology, Hospital Universitario Central de Asturias, Oviedo, Spain.Department of Pneumology, Hospital Clínico San Carlos, Madrid, Spain.Department of Pneumology, Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain.Department of Pneumology, Hospital Universitario de La Princesa/Instituto de Investigación Sanitaria (IIS-IP), Madrid, Spain.Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain.Department of Pneumology, Hospital Universitario Reina Sofia, Córdoba, Spain.Department of Pneumology, Hospital Galdakao-Usansolo, Galdakao, Spain.Department of Pneumology, Hospital Universitario de La Plana, Vila-real, Spain.Department of Pneumology, Hospital Universitario Son Espases IdISPa, Palma de Mallorca, Spain.Sección Urgencias Medicina - Neumología, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, Spain.Department of Pneumology, Hospital Universitario de Cruces, Bilbao, Spain.Department of Pneumology, Hospital Universitario de Guadalajara, Guadalajara, Spain.Department of Pneumology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain ; Medical-Surgical Unit of Respiratory Diseases, Virgen del Rocio University Hospital, Biomedicine Institute of Seville (IBiS), Seville, Spain.Department of Pneumology, Hospital Universitario Dr Peset, Valencia, Spain.Department of Pneumology, Hospital Universitario Lucus Augusti, Lugo, Spain.Department of Pneumology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.Department of Pneumology, Hospital Clínico Universitario Virgen de la Arrinxaca, Murcia, Spain.Department of Pneumology, Hospital Comarcal de Inca, Inca, Spain.Pneumology Department, Hospital Arnau de Vilanova-Lliria, Valencia, Spain.Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomédica Sant Pau (IIB Sant Pau), Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.Department of Pneumology, Hospital Galdakao-Usansolo, Galdakao, Spain.Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomédica Sant Pau (IIB Sant Pau), Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26270415

Citation

Miravitlles, Marc, et al. "What Pulmonologists Think About the asthma-COPD Overlap Syndrome." International Journal of Chronic Obstructive Pulmonary Disease, vol. 10, 2015, pp. 1321-30.
Miravitlles M, Alcázar B, Alvarez FJ, et al. What pulmonologists think about the asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2015;10:1321-30.
Miravitlles, M., Alcázar, B., Alvarez, F. J., Bazús, T., Calle, M., Casanova, C., ... Plaza, V. (2015). What pulmonologists think about the asthma-COPD overlap syndrome. International Journal of Chronic Obstructive Pulmonary Disease, 10, pp. 1321-30. doi:10.2147/COPD.S88667.
Miravitlles M, et al. What Pulmonologists Think About the asthma-COPD Overlap Syndrome. Int J Chron Obstruct Pulmon Dis. 2015;10:1321-30. PubMed PMID: 26270415.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - What pulmonologists think about the asthma-COPD overlap syndrome. AU - Miravitlles,Marc, AU - Alcázar,Bernardino, AU - Alvarez,Francisco Javier, AU - Bazús,Teresa, AU - Calle,Myriam, AU - Casanova,Ciro, AU - Cisneros,Carolina, AU - de-Torres,Juan P, AU - Entrenas,Luis M, AU - Esteban,Cristóbal, AU - García-Sidro,Patricia, AU - Cosio,Borja G, AU - Huerta,Arturo, AU - Iriberri,Milagros, AU - Izquierdo,José Luis, AU - López-Viña,Antolín, AU - López-Campos,José Luis, AU - Martínez-Moragón,Eva, AU - Pérez de Llano,Luis, AU - Perpiñá,Miguel, AU - Ros,José Antonio, AU - Serrano,José, AU - Soler-Cataluña,Juan José, AU - Torrego,Alfons, AU - Urrutia,Isabel, AU - Plaza,Vicente, Y1 - 2015/07/15/ PY - 2015/8/14/entrez PY - 2015/8/14/pubmed PY - 2016/4/26/medline KW - ACOS KW - COPD KW - asthma KW - guidelines KW - survey SP - 1321 EP - 30 JF - International journal of chronic obstructive pulmonary disease JO - Int J Chron Obstruct Pulmon Dis VL - 10 N2 - BACKGROUND: Some patients with COPD may share characteristics of asthma; this is the so-called asthma-COPD overlap syndrome (ACOS). There are no universally accepted criteria for ACOS, and most treatments for asthma and COPD have not been adequately tested in this population. MATERIALS AND METHODS: We performed a survey among pulmonology specialists in asthma and COPD aimed at collecting their opinions about ACOS and their attitudes in regard to some case scenarios of ACOS patients. The participants answered a structured questionnaire and attended a face-to-face meeting with the Metaplan methodology to discuss different aspects of ACOS. RESULTS: A total of 26 pulmonologists with a mean age of 49.7 years participated in the survey (13 specialists in asthma and 13 in COPD). Among these, 84.6% recognized the existence of ACOS and stated that a mean of 12.6% of their patients might have this syndrome. In addition, 80.8% agreed that the diagnostic criteria for ACOS are not yet well defined. The most frequently mentioned characteristics of ACOS were a history of asthma (88.5%), significant smoking exposure (73.1%), and postbronchodilator forced expiratory volume in 1 second/forced vital capacity <0.7 (69.2%). The most accepted diagnostic criteria were eosinophilia in sputum (80.8%), a very positive bronchodilator test (69.2%), and a history of asthma before 40 years of age (65.4%). Up to 96.2% agreed that first-line treatment for ACOS was the combination of a long-acting β2-agonist and inhaled steroid, with a long-acting antimuscarinic agent (triple therapy) for severe ACOS. CONCLUSION: Most Spanish specialists in asthma and COPD agree that ACOS exists, but the diagnostic criteria are not yet well defined. A previous history of asthma, smoking, and not fully reversible airflow limitation are considered the main characteristics of ACOS, with the most accepted first-line treatment being long-acting β2-agonist/inhaled corticosteroids. SN - 1178-2005 UR - https://www.unboundmedicine.com/medline/citation/26270415/What_pulmonologists_think_about_the_asthma_COPD_overlap_syndrome_ L2 - https://dx.doi.org/10.2147/COPD.S88667 DB - PRIME DP - Unbound Medicine ER -